Live price temporarily unavailable.
TScan Therapeutics (TCRX) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $1.08M | $10.1M | $13.5M | $21.0M | $2.82M | $10.3M |
| Growth (year over year) | — | +834.7% | +33.5% | +55.5% | −86.6% | +266.7% |
| Operating income | −$26.2M | −$48.6M | −$66.6M | −$93.5M | −$134.8M | −$135.8M |
| Operating margin | −2417.8% | −479.6% | −492.3% | −444.0% | −4787.7% | −1315.4% |
| Net income | −$26.1M | −$48.6M | −$66.2M | −$89.2M | −$127.5M | −$129.8M |
| Net margin | −2408.0% | −479.5% | −489.3% | −423.9% | −4527.7% | −1256.8% |
| EPS (diluted) | −$28.52 | −$4.17 | −$2.75 | −$1.36 | −$1.14 | −$1.00 |
| Balance sheet | ||||||
| Cash and equivalents | $34.8M | $161.4M | $120.0M | $133.4M | $178.7M | $152.4M |
| Total assets | $49.7M | $188.1M | $199.1M | $272.1M | $371.1M | $228.8M |
| Total liabilities | $32.5M | $27.3M | $99.7M | $121.3M | $130.1M | $105.7M |
| Long-term debt | — | — | $29.3M | $26.7M | $32.1M | $32.5M |
| Shareholders' equity | −$42.5M | $160.8M | $99.4M | $150.9M | $241.0M | $123.1M |
| Cash flow | ||||||
| Operating cash flow | −$3.02M | −$48.7M | −$66.5M | −$61.4M | −$110.8M | −$135.3M |
| Capital expenditure | $4.24M | $9.94M | $4.22M | $3.15M | $3.83M | $4.41M |
| Free cash flow | −$7.26M | −$58.6M | −$70.7M | −$64.5M | −$114.6M | −$139.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.05M | $665.0K | $2.17M | $3.08M | $2.51M | $2.57M | $982.0K | $1.05M |
| Growth (year over year) | −73.0% | −90.8% | +283.6% | +473.9% | +139.4% | +286.0% | −54.8% | −65.8% |
| Operating income | −$32.6M | −$36.7M | −$36.3M | −$38.7M | −$37.1M | −$23.9M | −$29.1M | −$30.5M |
| Operating margin | −3109.8% | −5520.6% | −1669.7% | −1256.6% | −1475.6% | −929.4% | −2967.3% | −2901.3% |
| Net income | −$29.9M | −$35.8M | −$34.1M | −$37.0M | −$35.7M | −$23.0M | −$28.7M | −$30.4M |
| Net margin | −2849.1% | −5384.8% | −1571.9% | −1201.3% | −1422.1% | −895.1% | −2919.1% | −2888.6% |
| EPS (diluted) | −$0.25 | −$0.29 | −$0.26 | −$0.28 | −$0.28 | −$0.18 | −$0.22 | −$0.23 |
| Balance sheet | ||||||||
| Cash and equivalents | $133.1M | $178.7M | $154.1M | $169.4M | $169.5M | $152.4M | $128.1M | $100.2M |
| Total assets | $348.0M | $371.1M | $332.7M | $298.6M | $262.2M | $228.8M | $202.0M | $171.5M |
| Total liabilities | $118.9M | $130.1M | $122.5M | $121.8M | $118.2M | $105.7M | $105.1M | $102.4M |
| Long-term debt | $30.6M | $32.1M | $32.2M | $32.3M | $32.4M | $32.5M | $32.7M | $21.1M |
| Shareholders' equity | $229.1M | $241.0M | $210.2M | $176.7M | $144.0M | $123.1M | $96.9M | $69.0M |
| Cash flow | ||||||||
| Operating cash flow | −$27.9M | −$27.4M | −$37.6M | −$33.3M | −$32.5M | −$32.0M | −$24.3M | −$27.5M |
| Capital expenditure | $1.37M | $888.0K | $1.53M | $1.28M | $1.43M | $171.0K | $70.0K | $493.0K |
| Free cash flow | −$29.3M | −$28.3M | −$39.1M | −$34.5M | −$33.9M | −$32.2M | −$24.3M | −$28.0M |
From TScan Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning TScan Therapeutics in our feed yet.